has come out with its second quarter (July-September) earnings estimates for the Pharmaceuticals sector. The brokerage house expects Pfizer
to report net profit at Rs 78.3 crore, up 8.4 percent quarter-on-quarter.
Net Sales are expected to increase by 8.1 percent Q-o-Q (up 5.8 percent Y-o-Y) to Rs 542 crore, according to Centrum.
Earnings before interest, tax, depreciation and amortisation (EBITDA) are likely to rise by 11.7 percent Q-o-Q (down 1.1 percent Y-o-Y) to Rs 113 crore.
Centrum's report on Pfizer
We expect Pfizer to report revenue growth of 6% YoY and 8% QoQ to Rs5.42bn. Pfizer’s flagship brands, namely, Minipress XL, Mucaine, Wysolone, Corex-Dx, Autrin and Prevenar 13 are likely to report double-digit growth during the quarter.
Pfizer is expected to report 42% YoY and 8% QoQ growth in net profit to Rs783mn from Rs553mn due to lower tax rate. We expect tax rate to decline to 34.9% from 45.1% of PBT.
Disclaimer: The views and investment tips expressed by investment experts on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.